Carcinoma, Non-Small-Cell Lung, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Urothelial Carcinoma
Conditions
Keywords
NSCLC, Adenocarcinoma of lung, Lung cancer, Squamous cell lung cancer, Malignant melanoma, Urothelial cancer, Non-small-cell lung cancer, Non small cell lung cancer, Non-small-cell lung carcinoma, Non small cell lung carcinoma, HNSCC, Head and neck squamous cell carcinoma
Brief summary
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab (Part 1), and in combination with pembrolizumab standard dose, and Standard of Care carboplatin and pemetrexed (Part 2 - subjects with stage IV, non-squamous metastatic NSCLC). CAN04, pembrolizumab. carboplatin and pemetrexed will be administered intravenously.
Interventions
DRUGCAN04
Administered intravenously
DRUGPembrolizumab
Administered intravenously
DRUGCarboplatin
Administered intravenously
DRUGPemetrexed
Administered intravenously
Sponsors
Cantargia AB
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(Part 1): * Subjects with metastatic or locally advanced, incurable non-small-cell lung cancer (NSCLC \[adenocarcinoma, adenosquamous, or squamous\]), head and neck squamous cell carcinoma (HNSCC), urothelial cancer, or malignant melanoma who have exhausted or declined available standard therapy. * Subjects progressing on previous treatment with a checkpoint inhibitor targeting thePD-1/PD-L1 pathway, alone or in combination with chemotherapy after previously having achieved stable disease or better and stayed on such therapy for ≥12 weeks. * Primary or metastatic lesion suitable for biopsy and willingness to undergo repeat biopsies as appropriate. * Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Inclusion Criteria (Part 2): * Subjects with histologically confirmed non-squamous metastatic (stage IV) NSCLC, without option for locoregional treatment with curative intent. * Subjects who have not received prior systemic anti-cancer therapy for the locally advanced or metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease. * Ability to safety undergo pre-treatment (if no archival biopsy is available) and on-treatment tumor biopsies. * Subject consents to retrieval of archival tumor tissue for screening in case no fresh biopsy is performed during screening. * Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing.
Exclusion criteria
(Parts 1 and 2): * Subjects with NSCLC tumors with genetic alteration or mutation, for which FDA-approved targeted therapy is available. * Treatment with systemic anticancer treatments, investigational products, or major surgery within 4 weeks before first dose of study drug or 5 half-lives, whichever is shorter. Subjects should have recovered from previous treatment toxicity (except hair loss and peripheral neuropathy). * History of uncontrolled brain metastasis. * Subject has received extended field radiotherapy ≤4 weeks before the start of treatment (≤2 weeks for limited field radiation to alleviate symptoms), and who has not recovered from related side effects of such therapy (except for hair loss). * Subjects who have previously experienced an immune-related adverse event (irAE) to pembrolizumab, for which permanent discontinuation is required. Subjects without a formal contraindication due to previous irAE are not eligible if the AE has not resolved or requires steroids (\>10 mg prednisone-equivalent per day) for ongoing management. * Subjects with active severe infection requiring oral antibiotics. * Clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting. * Uncontrolled or significant cardiovascular disease. * History of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses \>10 mg/day). * HIV patients can be enrolled if the infection is adequately controlled. * Known bleeding disorder or coagulopathy. Subjects on stable anticoagulant therapy are allowed. * Known or suspected allergy to study treatment or related products. * Women who are pregnant or breastfeeding, or trying to become pregnant. * Patients with chronic viral hepatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with grade ≥3 TEAEs (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with grade ≥3 TEAEs (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with 1 or more SAEs (serious adverse events) (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with 1 or more SAEs (serious adverse events) (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with 1 or more SAEs (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with 1 or more SAEs (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with 1 or more TEAEs leading to dose modifications (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with 1 or more TEAEs leading to dose modifications (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with 1 or more TEAEs leading to dose modifications (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with 1 or more TEAEs leading to dose modifications (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Frequency of TEAEs (treatment-emergent adverse events) (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Frequency of TEAEs (treatment-emergent adverse events) (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of participants with DLTs (dose-limiting toxicities) (Part 1) | Up to day 28 |
| Number of participants with DLTs (dose-limiting toxicities) (Part 2) | Up to day 28 |
| Number of subjects with grade ≥3 TEAEs (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
| Number of subjects with grade ≥3 TEAEs (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum concentrations of CAN04 and pembrolizumab (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Antidrug antibodies (ADAs) against CAN04 | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Change in serum IL-6 (interleukin-6) concentration (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Change in serum IL-6 (interleukin-6) concentration (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Change in serum CRP (C-reactive protein) concentration (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Change in serum CRP (C-reactive protein) concentration (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Overall response rate (ORR) (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | Proportion of subjects with partial response (PR) or complete response (CR) to study treatment as defined by iRECIST (immune-related response evaluation criteria in solid tumors) and measured by radiological assessment (CT/MRI scan) |
| Overall response rate (ORR) (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | Proportion of subjects with partial response (PR) or complete response (CR) to study treatment as defined by iRECIST (immune-related response evaluation criteria in solid tumors) and measured by radiological assessment (CT/MRI scan) |
| Progression free survival (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Progression free survival (Part 2) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
| Overall survival (Part 1) | Up to 36 months after 1st dose of last subject (or death) | — |
| Overall survival (Part 2) | Up to 36 months after 1st dose of last subject (or death) | — |
| Serum concentrations of CAN04 and pembrolizumab (Part 1) | From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first | — |
Countries
United States
Outcome results
None listed